Latest Information

20.11.08 - Latest NAV performance

13.11.08 - Investment Bulletin

12.11.08 - Latest Fund Factsheets

07.11.08 - Pick of the Week

05.11.08 - 'Old Europe'

 

Fund Prices (20 Nov 2008)

A Share

£  88.41

£130.57

£132.16

£  81.01

£101.77

£  64.08

B Share

£  86.36

£128.05

£130.84

£  76.25

£101.03

£108.86

Funds under Management - £176.7 million

Unlike most fund management companies, Bedlam is structured to make investors money

Bedlam is structured to make investors money

      Pick of the Week

Bedlam is structured to make investors money Articles    
Bedlam is structured to make investors money Financials

Global Stock Writeups

 

Lihir Gold is a pure gold producer with one of the largest single deposits in the world. Using a gold price of just $340/oz the company currently conservatively estimates the mine has reserves of 20m ounces of gold. The company's 2004 average realised gold price was $399 which together with cash costs to mine the gold of $299 suggests that the reserves alone are conservatively worth US$2bn, or roughly AUD2.00 per share. With the current share price at just over AUD1.00 and the likelihood that the gold price will increase and cash costs decrease in 2005, the stock is cheap in absolute terms.

Sedol Type Price Date

6518596

Buy AUD 2.642 31/03/2006

6518596

Buy AUD 1.993 16/02/2006

6518596

Buy AUD 2.12 17/11/2005

6518596

Buy AUD 1.345 01/08/2005

6518596

Buy AUD 1.091 11/02/2005

 

Lundbeck is a medium-sized pharmaceutical company which specialises in diseases of old age and the central nervous system. While earnings growth is currently very strong, there is a huge risk to earnings from 2012, when a large number of the existing portfolio of drugs face patent expiry. The late-stage research pipeline, which last year had still looked very strong, has suffered a series of disappointments, making it less likely that the lost sales can be replaced; we therefore decided to sell the stock.

Lundbeck. The pharmaceutical sector is trading at a 15-year-low, as the majors are plagued with patent expiries and more aggressive pricing regimes. Lundbeck benefits from a reasonably young portfolio of drugs that play well to current demographic trends - focussing on Alzheimer's, depression and Parkinson's disease, which should have above average growth rates.

Sedol Type Price Date
7085259 Sell DKK 114.88 15/08/2008
7085259 Buy DKK 145.92 30/10/2007

Back to Global Stock Writeups categories

Back to Global Portfolio

 

View Stocks A - Z

Home
About Bedlam
Investors
Funds
Segregated Accounts
News
Archive
Financials
Contact Bedlam
www.intergage.co.uk